Gores Group Said to Mull Sale of Immunotherapy Business Therakos
U.S. buyout firm Gores Group is weighing a sale of immunotherapy company Therakos amid a boom in health care deals, according to people with knowledge of the matter.
Gores is working with Credit Suisse Group AG on the sale, which may value Therakos at about $1 billion, the people said, asking not to be identified because the process is private. Therakos may attract interest from other buyout firms and health care companies, the people said.